135 related articles for article (PubMed ID: 36633494)
1. Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017-2018.
Payne JY; Alkhouri N; Le P; Rothberg MB; Polanco P; Sakkal C; Dasarathy S
Hepatol Commun; 2023 Jan; 7(1):e0019. PubMed ID: 36633494
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
3. Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis.
DeBoer MD; Lin B; Filipp SL; Cusi K; Gurka MJ
Nutr Res; 2021 Apr; 88():34-43. PubMed ID: 33743323
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018.
Vilar-Gomez E; Vuppalanchi R; Mladenovic A; Samala N; Gawrieh S; Newsome PN; Chalasani N
Clin Gastroenterol Hepatol; 2023 Jan; 21(1):115-124.e7. PubMed ID: 34958922
[TBL] [Abstract][Full Text] [Related]
5. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
Zhang X; Heredia NI; Balakrishnan M; Thrift AP
PLoS One; 2021; 16(6):e0252164. PubMed ID: 34081733
[TBL] [Abstract][Full Text] [Related]
7. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
8. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.
Wong RJ; Liu B; Bhuket T
Aliment Pharmacol Ther; 2017 Nov; 46(10):974-980. PubMed ID: 28914448
[TBL] [Abstract][Full Text] [Related]
9. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
[TBL] [Abstract][Full Text] [Related]
10. The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population.
Jinjuvadia R; Antaki F; Lohia P; Liangpunsakul S
J Clin Gastroenterol; 2017 Feb; 51(2):160-166. PubMed ID: 27580477
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.
Michel M; Labenz C; Wahl A; Anders M; Armandi A; Huber Y; Galle PR; Sprinzl M; Schattenberg JM
AIDS; 2022 Oct; 36(12):1665-1674. PubMed ID: 35849074
[TBL] [Abstract][Full Text] [Related]
12. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
13. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database.
Alkhouri N; Almomani A; Le P; Payne JY; Asaad I; Sakkal C; Vos M; Noureddin M; Kumar P
BMC Gastroenterol; 2022 Jul; 22(1):366. PubMed ID: 35907827
[TBL] [Abstract][Full Text] [Related]
15. Clinical Correlates of Non-alcoholic Steatohepatitis in Nigerian Patients with Metabolic Syndrome.
Obasi E; Adekanle E; Ajayi NA; Ndububa DA
West Afr J Med; 2022 Apr; 39(4):407-414. PubMed ID: 35490415
[TBL] [Abstract][Full Text] [Related]
16. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
Shaji N; Singhai A; Joshi R
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
[TBL] [Abstract][Full Text] [Related]
17. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
18. Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.
Ortolan A; Lorenzin M; Tadiotto G; Russo FP; Oliviero F; Felicetti M; D'Incà R; Favero M; Piaserico S; Doria A; Ramonda R
Clin Rheumatol; 2019 Oct; 38(10):2843-2850. PubMed ID: 31254236
[TBL] [Abstract][Full Text] [Related]
19. [Predictors of liver fibrosis in patients with non-alcoholic fatty liver disease. The role of metabolic syndrome, insulin-resistance and inflammation].
Andreozzi P; Viscogliosi G; Colella F; Subic M; Cipriani E; Marigliano B; Verrusio W; Servello A; Ettorre E; Marigliano V
Recenti Prog Med; 2012 Dec; 103(12):570-4. PubMed ID: 23258240
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]